about
Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocolCost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial.Assessing depression in primary care with the PHQ-9: can it be carried out over the telephone?Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study).Cost-effectiveness of active monitoring versus antidepressants for major depression in primary health care: a 12-month non-randomized controlled trial (INFAP study)Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study).Impact of IPDE-SQ personality disorders on the healthcare and societal costs of fibromyalgia patients: a cross-sectional study.Cost-Utility of Group Acceptance and Commitment Therapy for Fibromyalgia Versus Recommended Drugs: An Economic Analysis Alongside a 6-Month Randomized Controlled Trial Conducted in Spain (EFFIGACT Study).Initial medication non-adherence: prevalence and predictive factors in a cohort of 1.6 million primary care patients.Functional Status, Quality of Life, and Costs Associated With Fibromyalgia Subgroups: A Latent Profile Analysis.Correction: Cost-Effectiveness of a Community Pharmacist Intervention in Patients with Depression: A Randomized Controlled Trial (PRODEFAR Study).Cost-utility of a psychoeducational intervention in fibromyalgia patients compared with usual care: an economic evaluation alongside a 12-month randomized controlled trial.Corrigendum to: "Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for depression: A randomized controlled superiority trial" [Eur. Neuropsychopharmacol. 23(2013)1057-1066].Clinical dimensions of fibromyalgia symptoms and development of a combined index of severity: the CODI index.Effectiveness of a psychoeducational treatment program implemented in general practice for fibromyalgia patients: a randomized controlled trial.[Impact of pharmaceutical intervention in preventing relapses in depression in Primary Care].[Do we really follow the Mediterranean diet?].Is major depression adequately diagnosed and treated by general practitioners? Results from an epidemiological study.Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.¿Cómo derivamos a salud mental desde atención primaria?[Non-cardiogenic acute pulmonary edema and recurrent leukopenia caused by hydrochlorothiazide]
P50
Q33490837-CA71E39C-D28C-4588-BBD4-49F6D7843339Q34374726-46BB05BC-87CB-4ACC-8690-C59A0F17D2FAQ34723758-A635E47A-17F4-446B-A648-E325AFA16BCCQ34947318-74271F18-331B-4A8E-8A94-E74EF1B45AC6Q35380186-984375BD-8422-43B6-A11E-550B6EBBDDBBQ35938110-1F7DB9ED-1CEA-4BE1-A4F7-B3E401CD333EQ36035193-05B0690B-5358-41CA-B79A-ED033BA92ABBQ38876474-0D8E7AB5-01F1-4165-AC9F-336BE113052FQ38946930-62DED1F8-D480-4F0D-A404-8E843D45614FQ41075626-66C57118-91EE-4EF6-B5B2-53D855647139Q43088139-20EE7E18-F3EF-404C-BEBE-F40FD548C043Q46589078-516AF07F-AEAD-4CF5-AB8C-E9AF21B4DB99Q48055948-7E82E12D-EC09-487F-A01C-CDE5234D15B5Q48476845-5D1397FF-AE8B-49D3-8E7C-DEECE3B7D1E6Q48911703-239347E5-CBC7-4E4F-849B-07F0AC3D8A43Q50436405-A6B0332C-DC4E-4DF6-8CEF-A4364FC9A2A9Q50737028-E8EFCF1D-ED6C-4DC3-A5DB-82991DA11E75Q51853983-A682DA23-CC5E-44FD-A684-43885CC22ED6Q51910373-09D25CD8-AB5F-44A7-B434-FBB97F9D2FA1Q60728414-B1E300F4-1427-4B47-A155-3985D018FA07Q73857125-0DEA4687-66AF-4344-9732-2F27CD4D3827
P50
description
researcher
@en
name
M T Peñarrubia María
@en
M T Peñarrubia María
@nl
type
label
M T Peñarrubia María
@en
M T Peñarrubia María
@nl
prefLabel
M T Peñarrubia María
@en
M T Peñarrubia María
@nl
P106
P31
P496
0000-0002-0322-4961